Experts call for urgent action to improve Alzheimer’s diagnosis across Europe
Eli Lilly and leading Alzheimer's disease experts have called...
Eli Lilly and leading Alzheimer's disease experts have called...
From Switzerland to Italy, ADI has taken part in key engagements on the European continent that convened industry leaders, clinicians,...
The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive decline was not...
The 35th Alzheimer Europe...
Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia...
These new data exhibit much higher prevalence rates of dementia in the Mediterranean and Southeastern European countries and a much larger variation of...
Lilly's next challenge will be getting European countries to reimburse Kisunla. Some cost-effectiveness watchdogs have taken issue with the...
Eli Lilly is calling on European countries to make...
(NASDAQ:AVXL), a biotech company with a market capitalization of $818 million that has delivered an impressive 86% return over the past year,...
European approval of Kisunla comes just over a year after it was approved in the U.S. for a similar indication. It has also been authorized to...